Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice

Menopause

Volumn 17, Issue 5, 2010, Pages 1040-1047

  Liang, Yayun ^a   Benakanakere, Indira ^a,b   Besch Williford, Cynthia ^a   Hyder, Ryyan S ^a   Ellersieck, Mark R ^c   Hyder, Salman M ^a,b  

^a Department of Biomedical Sciences ^*  (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

Breast cancer; Hormone therapy; Medroxyprogesterone; Progestin; Xenograft

Indexed keywords

ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORGESTREL; PROGESTERONE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; OVARIECTOMY; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR TUMOR;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HORMONE REPLACEMENT THERAPY; LYMPHATIC METASTASIS; MICE; MICE, NUDE; NORETHINDRONE; NORGESTREL; PROGESTERONE CONGENERS; TRANSPLANTATION, HETEROLOGOUS;

EID: 77957723055     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181d3dd0c     Document Type: Article

References (31)

1. Liang Y, Besch-Williford C, Brekken RA, Hyder SM. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating anti-tumor therapeutics. Cancer Res 2007;67:9929-9936.
2. Feeley KM, Wells M. Hormone replacement therapy and the endome-trium. J Clin Pathol 2001;54:435-440.
3. Van Gorp T, Neven P. Endometrial safety of hormone replacement therapy: review of literature. Maturitas 2002;42:93-104.
4. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy post-menopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253.
5. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
6. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004; 101:1490-1500.
7. Fu XD, Giretti MS, Goglia L, et al. Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer 2008;8:166.
8. Wu J, Brandt S, Hyder SM. Ligand-and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothe-lial growth factor levels in human breast cancer cells. Mol Endocrinol 2005;19:312-326.
9. Schindler AE. Differential effects of progestins on hemostasis. Maturitas 2003;1:S31-S37.
10. Campagnoli C, Abbà C, Ambroggio S, Lotano MR, Peris C. Differential effects of various progestogens on metabolic risk factors for breast cancer. Gynecol Endocrinol 2007;1:22-31.
11. El Etreby MF, Liang Y. Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat 1998;49:109-117. (Pubitemid 28279588)
12. Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res 1998;58:392-395. (Pubitemid 28087395)
13. Hyder SM, Chiappetta C, Stancel GM. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 2001;92:469-473.
14. Mirkin S, Wong BC, Archer DF. Effects of 17A-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and thrombospondin-1 messenger RNA in breast cancer cells. Int J Gynecol Cancer 2006;2:560-563.
15. Carnevale RP, Proietti CJ, Salatino M, et al. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol 2007;21: 1335-1358.
16. Efeyan A, Fabris V, Merani S, Lanari C, Molinolo AA. Establishment of two hormone-responsive mouse mammary carcinoma cell lines derived from a metastatic mammary tumor. Breast Cancer Res Treat 2004;83: 233-244.
17. Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas 2009;64: 80-85.
18. Nath A, Sitruk-Ware R. Parenteral administration of progestins for hormonal replacement therapy. Eur J Contracept Reprod Health Care 2009;14:88-96.
19. Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004;109:721-727.
20. Soderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123-128.
21. De Lignieres B. Effects of progestogens on the postmenopausal breast. Climacteric 2003;5:229-235.
22. Raafat AM, Li S, Bennett JM, Hofseth LJ, Haslam SZ. Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model. J Cell Physiol 2001;187: 81-89.
23. Lydon JP, Ge G, Kittrell FS, Medina D, O'Malley BW. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res 1999;59:4276-4284.
24. Moore MR, Conover JL, Franks KM. Progestin effects on long-term growth, death, and Bcl-xL in breast cancer cells. Biochem Biophys Res Commun 2000;277:650-654.
25. Behera MA, Dai Q, Garde R, Saner C, Jungheim E, Price TM. Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells [e-pub]. Am J Physiol Endocrinol Metab 2009.
26. Liang Y, Hyder SM. Proliferation of endothelial and tumor epithelial cells by progestin-induced VEGF from human breast cancer cells: paracrine and autocrine effects. Endocrinology 2005;146:3632-3641.
27. Giulianelli S, Cerliani JP, Lamb CA, et al. Carcinoma-associated fibro-blasts activate progesterone receptors and induce hormone independent mammary tumor growth: a role for the FGF-2/FGFR-2 axis. Int J Cancer 2008;123:2518-2531.
28. Sartorius CA, Harvell DM, Shen T, Horwitz KB. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res 2005;65:9779-9788.
29. Liang Y, Wu J, Stancel GM, Hyder SM. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. J Steroid Biochem Mol Biol 2005;93:173-182.
30. Carroll CE, Ellersieck MR, Hyder SM. Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells. Menopause 2008;15:570-574.
31. Carroll CE, Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM. Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors. Menopause 2010;17:178-184.